<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000100.v3.p1" parentStudy="phs000100.v3.p1" createDate="2011-04-11" modDate="2011-04-11">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>Michael Boehnke</td><td>University of Michigan, Ann Arbor, MI, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Francis Collins</td><td>NHGRI, NIH, Bethesda, MD, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Richard Bergman</td><td>University of Southern California, Los Angeles, CA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Jaakko Tuomilehto</td><td>National Public Health Institute, Helsinki, Finland</td></tr>
		<tr><td>Principal Investigators</td><td>Karen Mohlke</td><td>University of North Carolina, Chapel Hill, NC, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>The Finland-United States Investigation of NIDDM Genetics (FUSION) Study</StudyNameEntrez>
	<StudyNameReportPage>The Finland-United States Investigation of NIDDM Genetics (FUSION) Study</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The Finland-United States Investigation of NIDDM Genetics (FUSION) study is a long-term effort to identify genetic variants that    predispose to type 2 diabetes (T2D) or that impact the variability of T2D-related quantitative traits. The initial effort involved    linkage analysis of affected-sibling-pair (ASP) families based on over 5,000 individuals living in Finland, and association fine mapping    based on these family members and additional T2D cases and controls.  Recently we completed a genome-wide association scan on 1161 T2D    cases and 1174 normal glucose tolerant (NGT) controls.  Individual-level data is available here for the 919 T2D cases and 787 NGT    controls who reconsented to the use of their data or are deceased. Version 3 adds individual-level data for additional phenotypic variables.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<b>Sample inclusion criteria and exclusion criteria</b>           <p><b>Cases:</b>  644 FUSION and 275 Finrisk 2002 T2D cases as defined by WHO 1999 criteria of fasting plasma glucose &#8805; 7.0 mmol/l or           2-h plasma glucose &#8805; 11.1 mmol/l, by report of diabetes medication use, or based on medical record review.  FUSION cases with           known or probable type 1 diabetes among their first degree relatives were excluded.  The 644 FUSION cases each reported at least           one T2D sibling; the 275 Finrisk 2002 cases came from a Finnish population-based risk factor survey.</p>            <p><b>Controls:</b>  331 FUSION and 456 Finrisk 2002 NGT controls as defined by WHO 1999 criteria of fasting glucose &lt; 6.1 mmol/l           and 2-h glucose &lt; 7.8 mmol/l.  FUSION controls include 119 subjects from Vantaa, Finland, who were NGT at ages 65 and           70 years, and 212 NGT spouses of FUSION subjects.  The controls were approximately frequency matched to the cases by age, sex,           and birth province.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="9614613"/>
		</Publication>
		<Publication>
			<Pubmed pmid="11032783"/>
		</Publication>
		<Publication>
			<Pubmed pmid="11032784"/>
		</Publication>
		<Publication>
			<Pubmed pmid="14988269"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17463248"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Diabetes Mellitus, Type 2"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>Michael Boehnke</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Francis Collins</AttName>
			<Institution>NHGRI, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Richard Bergman</AttName>
			<Institution>University of Southern California, Los Angeles, CA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Jaakko Tuomilehto</AttName>
			<Institution>National Public Health Institute, Helsinki, Finland</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Karen Mohlke</AttName>
			<Institution>University of North Carolina, Chapel Hill, NC, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Laura Scott</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Lori Bonnycastle</AttName>
			<Institution>NHGRI, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Timo Valle</AttName>
			<Institution>National Public Health Institute, Helsinki, Finland</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Heather Stringham</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Anne Jackson</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Tom Buchanan</AttName>
			<Institution>University of Southern California, Los Angeles, CA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Richard Watanabe</AttName>
			<Institution>University of Southern California, Los Angeles, CA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Peter Chines</AttName>
			<Institution>NHGRI, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Mike Erdos</AttName>
			<Institution>NHGRI, NIH, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Cristen Willer</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Gon&#231;alo Abecasis</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Funding Source for Genotyping">
			<AttName>HHSN268200782096C. NIH contract &quot;High throughput genotyping for studying the genetic contributions to human disease&quot;</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="FUSION (Finland-United States Investigation of NIDDM Genetics) Study" url="http://fusion.sph.umich.edu/"/>
	</StudyURLs>
	<StudyHistory><![CDATA[
<p>       <li>Oct 1994 - Apr 1996: FUSION 1 ASP family primary data collection</li>       <li>Dec 1996 - Aug 1998: FUSION 2 ASP primary data collection and collection of additional FUSION 1 family members</li>       <li>2000: FUSION 1 linkage genome scan papers published</li>       <li>2004: FUSION 2 linkage genome scan paper published</li>       <li>2004 - 2006: sampling of additional FUSION 1 and 2 family members and unrelated T2D cases and NGT controls from Finrisk 2002 and other studies</li>       <li>2006: Genome-wide association scan genotyping completed</li>       <li>2007: T2D genome-wide association scan paper published in <i>Science</i></li>     </p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIDDK</DacName>
      <DacFullName>NIDDK Central Repository GWAS Data Access Committee</DacFullName>
      <DacEmail>niddk-dac@mail.nih.gov</DacEmail>
      <DacPhone></DacPhone>
      <DacFax>301-480-3510</DacFax>
      <DacUrl>http://www3.niddk.nih.gov/researchprograms/repositories/FAQ.shtml</DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000100.v3.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
               http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000100.v3.p1
            </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000100.v3.p1" FileName="NIDDK_NCBI_dbGaP_DUC_2010February19.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>These data may be used scientists to address medical research questions.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>

<Analyses>
	<Analysis pha="2839" genomeBuild="36.3" snpBuild="129" analysisType="">
		<Description><![CDATA[
This genome-wide association study of Type 2 Diabetes (T2D) utilized 1161 Finnish case and 1174 Finnish control DNA samples that had been collected for the <a href="http://fusion.sph.umich.edu/"> FUSION</a> (Finland-United States Investigation of Non-Insulin-Dependent Diabetes Mellitus Genetics) and <a href="http://www.ktl.fi/portal/english/research__people___programs/health_promotion_and_chronic_disease_prevention/units/chronic_disease_epidemiology_unit/the_national_finrisk_study/"> FINRISK 2002 </a> studies. The samples were genotyped at the Johns Hopkins University Genetic Resources Core Facility (GRCF) SNP Center at the Center for Inherited Disease Research (CIDR) on the Illumina HumanHap300 BeadChip v.1.0 using the Illumina Infinium II assay protocol.
		]]></Description>
		<Method>Testing for T2D-Genotypes Association using Logistic Regression under the Additive Genetic Model</Method>
		<GtyPlatform probeNum="317503" snpBatchId="33879">
			<Vendor>Illumina</Vendor>
			<VendorURL>HumanHap300v1.1 used by FUSION</VendorURL>
			<Platform>HumanHap300v1 </Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
</Analyses>

</Study>

</Studies>

</GaPExchange>
